Previous 10 | Next 10 |
Weyco Group Inc. (WEYS) is expected to report for Q1 2024 Gladstone Land Corporation (LAND) is expected to report $0.16 for Q3 2023 PlayAGS Inc. (AGS) is expected to report $0.01 for Q3 2023 Ardmore Shipping Corporation (ASC) is expected to report $0.43 for Q3 2023 Sage Therapeuti...
Fulcrum Therapeutics Inc. (FULC) is expected to report $-0.44 for Q3 2023
CAMBRIDGE, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today a...
2023-09-25 14:10:47 ET Summary Fulcrum Therapeutics, Inc. has had some key potential catalysts resolved positively recently. These included the FDA lifted the clinical hold on Fulcrum's sickle-cell disease candidate, allowing the company's Phase 1b trial to move forward. The c...
CAMBRIDGE, Mass., Sept. 22, 2023 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that management will participate in a fireside c...
2023-09-18 17:06:48 ET Gainers: Gain Therapeutics ( NASDAQ: GANX ) +7% . QuidelOrtho ( QDEL ) +5% . ARS Pharmaceuticals ( SPRY ) +5% . ProFrac Holding ( ACDC ) +5% . Clean Energy Fuels ( CLNE ) +4% . L...
2023-09-13 09:00:30 ET FN Media Group Presents USA News Group News Commentary Vancouver, BC – September 13, 2023 – USA News Group – Sufferers of many different ailments saw reason to grow their hope in 2022 when the US Food and Drug Administr...
2023-09-12 17:27:39 ET Gainers: Rocket Pharmaceuticals ( RCKT ) +30% . Alset Capital Acquisition ( ACAX ) +14% . Veeco Instruments ( VECO ) +7% . InnovAge Holding ( INNV ) +4% . Fulcrum Therapeutics ( FULC ) +4% ...
2023-09-11 12:00:00 ET Summary Fulcrum Therapeutics focuses on rare genetic diseases with losmapimod in Phase 3 trial; stock is down 56% since February. Fulcrum's financial health is strong with $278.2M in cash; monthly cash burn approximates $7.484M, supporting operations till mi...
CAMBRIDGE, Mass., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that it has completed enrollment in REACH, a Pha...
News, Short Squeeze, Breakout and More Instantly...
Fulcrum Therapeutics Inc. Company Name:
FULC Stock Symbol:
NYSE Market:
Fulcrum Therapeutics Inc. Website:
CAMBRIDGE, Mass., June 12, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today a...
CAMBRIDGE, Mass., June 06, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today a...
Aileron Therapeutics Inc. (ALRN) is expected to report for Q1 2024 DZS Inc. (DZSI) is expected to report $-0.09 for Q1 2024 Bitfarms Ltd. (BITF) is expected to report $-0.03 for Q1 2024 180 Degree Capital Corp. (TURN) is expected to report for quarter end 2024-03-31 Abacus Life In...